Table 1.

Definitions of hypertriglyceridaemia.

2018 AHA/ACC Clinical Practice Guidelines *	NCEP ATP III	Endocrine Society	ESC/EAS Guidelines
Normal: <2.0 mmol/L Moderate: 2.0–5.6 mmol/L Severe: >5.6 mmol/L	Normal: <1.7 mmol/L Borderline high: 1.7–2.3 mmol/L High: 2.3–5.6 mmol/L Very High: >5.6 mmol/L	Normal: <1.7 mmol/L Mild: 1.7–2.3 mmol/L Moderate: 2.3–11.2 mmol/L Severe: 11.2–22.4 mmol/L Very severe: >22.4 mmol/L	Normal: <1.7 mmol/L Mild to Moderate: >1.7 mmol/L Severe: >10.0 mmol/L

* In the 2021 American College of Cardiology (ACC) Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients with Persistent Hypertriglyceridemia, persistent hypertriglyceridaemia was defined as a fasting TG level of >1.7mmol/L following a minimum of 4 to 12 weeks of lifestyle intervention, a stable dose of maximally tolerated statin when indicated, as well as evaluation and management of secondary causes of hypertriglyceridaemia [6]. ACC: American College of Cardiology; AHA: American heart association; EAS: European atherosclerosis society; ESC: European society of cardiology; NCEP ATP III: National cholesterol education programme Adult Treatment plan III.